{"name":"Indapta Therapeutics, INC.","slug":"indapta-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxOU3hfa0JPVU9zTXZWc1A0WkRUYVhLZlB3c1RPc1FxVU1mSFBlN0lQT0tOMHlvbXJwRlZMbFhxdV9zTkxfWXBkUFdGcWZaQkFRMHpNMWFvUGpTVjlHZzluYXp4QXI5TlJrT0NXR2JwMGFrd3hZeFdyUzVuR0NuZnVuSkEzdjRRUEFqWXhPUjhsRXBEeUFIZl9jLVc1VVoyaHRmWFRVTWw0S3pFOV9xMlYzU2RpR2ZEV1dieWpjRTd4eElFY2V6UkdhdWNOd0NUUXk1Um95SjhVNHRRRUxXNGtzc2d4a2NkcjN3YmlUWEZCWTlkc2U4YlNyMW50XzFzdw?oc=5","date":"2026-02-16","type":"trial","source":"Investing News Network","summary":"IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Investing News Network","headline":"IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1RZG9NZGl5T2FCei1wNFBRNlF5bnVCSW1DeGxhRWFaZ1B1bVUzRHVkZW5qdDlnRld2RHdLa3hqVXlVZUZJVnhQX2w0U25EUWVPeFo3N1dJWHcxV1BwRDBoM0tWYkwteWJ3Nnlvc1RR?oc=5","date":"2025-03-13","type":"pipeline","source":"Pharmaceutical Executive","summary":"Mark Frohlich: A ‘Natural’ Leader - Pharmaceutical Executive","headline":"Mark Frohlich: A ‘Natural’ Leader","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxQMnowYkx2bnE5WjV3QXMyaWJkTnNYYWo2QXVHQ0J1b2pQYWprdG1yeTR0bGZEM25EYWl6TWhOZ2VMQzFJWFQ5V2ZScnVMRVZsaXA0ekVpV0hQMEJJal9pbGZWVk9tM2lUR0ZUQllKTXBKdGIweDdueENqYnVoWUZrTVhZYURvX1lfOHJycklDNXkwR2NGYm1wdllNaGNRY2JRMGlENTBmUzFCcWl5bXdBdDZpdDBCWlVqQ1NYeVZVOWJBZ2lZdzc3Vmx3eFNiVFV4cTV6N1pqWWo0MEJYVE1XS0RJdWNOOTVtSENF?oc=5","date":"2024-12-17","type":"trial","source":"BioSpace","summary":"Indapta Therapeutics Secures $22.5 Million to Advance Clinical Trials of Innovative Cancer and Autoimmune Treatments - BioSpace","headline":"Indapta Therapeutics Secures $22.5 Million to Advance Clinical Trials of Innovative Cancer and Autoimmune Treatments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxPWVU5aGxYSG03UUk3c2JUc3QtWE95TzFLN2t0NkcwODVtano1V3ZkMHZHeDNRTDJfWGxXSTZReTlCWllTcC1OUUh0UUJuYXlJX05FSFRyUzVneVV0Mjh6WDZmcWlOamxmTU15cVhkbzZ0aWJwblpEaDNDbEt5bVJLTjVaRmRPWWt1UW43Z3JBTHpYam5EVDlGVVlEYmJzdlBKeXRFcDEzZFg2Wmk5ZVh1akFSemNNN2JHUzNYcmJ6Ymw0aDEyazFEMVl1MUlKR214VEx1YnZYandBbHBMVEtPX1dNOHozSHFCaGFVSA?oc=5","date":"2024-12-06","type":"trial","source":"Business Wire","summary":"Indapta Therapeutics Announces Clinical Study Collaboration With Sanofi on Multiple Myeloma Program - Business Wire","headline":"Indapta Therapeutics Announces Clinical Study Collaboration With Sanofi on Multiple Myeloma Program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgJBVV95cUxOLTNGclp3R1k1Ql95djVkdTRCRG1mbmlmSDhFTm52MlJGZjdaNG9qU1VfbWxyUUVoOWs3aUJvUUY2M3o4bEtfUExtVXNOY1F0MUU3MzRWbFRSYmZMb0V2eEJuUnNTU1cxQUVFbXZieW1TQmxXRWxuUDRtZlM2allWeUpNQlVvN0gyNHNaSE9CTjQ0TE84ZTJJT0tlSlQtX0FCQWNqMXdhMElMa1lRdDgtZDRRNU84U1otT2ZCbXdEekttb3FKSFNZbnIxRndueUw4S0d4OTR5V3BpNkV0dTNTRzVMM2oxVGxrd1p3TFZCZmNpdXIyZGJkWm1xOW83aDM0UFV2WUM3cTdWOHVrUDg2VHJqcC1YNmxmbWl4VmlhNjlKYkZHMXc?oc=5","date":"2024-11-11","type":"trial","source":"PR Newswire","summary":"NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire","headline":"NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeuti","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxORnpDQ0Q3aWVsa2lyYW90Szd0aFlXdGdQYk1tenVPN0lLeEV3TE44cWlrbjNKeXBadkJ0NHFSczd2RDh3dHBDeEkybDRDNDVEQVdreS1CMzEzMHg2WHlUcE1MdXlVeC01eU9zNXkzYUxqRVlaNGk3aWRNcXdpSGQ0aWNNZEhlUm9vcTlUa0x5d1Z1T2dQbnhHMGNtaWpKVTJrREdOdzlfRTBqNHc5alJ1RmlrejE5a3hZOVozWGJ3ZTBRVFR1T0tzaXdwRmNCY2RiVFBRdFZhbDNNWkVrYVZ3WTRUeUFRbkZKRjBhLU9WNTB2eGFCeDFpRWhhVHdsR1pfTGI0cTh6akNlQ2dRdnlFZ2ZTOGZ3UQ?oc=5","date":"2024-11-07","type":"trial","source":"BioSpace","summary":"Indapta Therapeutics Presents Clinical and Preclinical Data of Allogenic Natural Killer Cell Therapy at Society for Immunotherapy of Cancer Meeting - BioSpace","headline":"Indapta Therapeutics Presents Clinical and Preclinical Data of Allogenic Natural Killer Cell Therapy at Society for Immu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNblptZHcwOHJEbGpNMHVIOGM4Y3hRNENxaXBhd01zNmg3aTBtZHRXdTZUXzZPWjM1blNURUZRVVZfYk5GQ3VBNzVKUExZZGFwZXB6aEstVHdMVmhYVDBPUHFheXYydkNWVTJfbE9GYlZIVlNsVkhsY1l3cEFwdXNITVE5WlpCbGlzVW9oSFFMZFREN2VUZW9LM2liT2s?oc=5","date":"2024-08-08","type":"regulatory","source":"RegMedNet","summary":"Cell therapy weekly: FDA clears g-NK cell therapy for Phase I MS trial - RegMedNet","headline":"Cell therapy weekly: FDA clears g-NK cell therapy for Phase I MS trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNelYwRVJZRElNV0tocUxUeVVhT1VhQkYyNDNGUTZWUGpKRFNkQVgtOGY2bzdMcnhjN3dJcTZEcXFMZGJscnpBUmItbGFfTmlNVGcyTmNSRG9wXy1laU1FNEFwNnAyTHBKT1JkTWY2UVZ4UnJ5al9MNnI1YUozU1VWc2FPVlhBUVJXbzNLT1BxTkdjOF96U1RmNmktd1RneDNHM2RDMXJXcTJIN2ZHVVNaWTJlUGJmdTA5NGZSekVLQ1A?oc=5","date":"2022-02-10","type":"pipeline","source":"Fierce Biotech","summary":"Indapta snags $50M financing and signs on former Juno exec as CEO - Fierce Biotech","headline":"Indapta snags $50M financing and signs on former Juno exec as CEO","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2022-02-10","type":"pipeline","source":"Business Wire","summary":"Indapta Therapeutics Names Mark W. Frohlich, M.D., Chief Executive Officer and Raises Over $50 Million in Series A Financing and Commitments to Advance Development of G-NK Cell Therapy to Treat Multip","headline":"Indapta Therapeutics Names Mark W. Frohlich, M.D., Chief Executive Officer and Raises Over $50 Million in Series A Finan","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}